Take-Back and Anti-Diversion Practices

Source: CEPOP’s Takeback and Anti-Diversion Working Group

During a time where overdoses and deaths due to prescription opioids are at the highest levels in recorded history (1), significant efforts must be made to combat the opioid and prescription drug abuse epidemic that is affecting communities across the country. The statistics surrounding the epidemic are startling, exacerbating the need for appropriate methods in which to safely use and dispose of excess, legally-obtained opioid medications. (more…)

‘CEPOP Salutes’ Webinar – August 2016

Source: CEPOP

The first of the “CEPOP Salutes” webinar recordings is now available. This initial webinar highlights the work of hospital networks and their efforts to reduce opioid-related adverse events. The mid-August webinar ran for a bit over an hour and included a significant question and answer period from webinar participants. We look forward to providing additional webinars on related efforts in the coming months. (more…)

National Pain Strategy: A Comprehensive Population Health-Level Strategy for Pain

Source: The National Institute of Neurological Disorders and Stroke (NINDS) Office of Pain Policy

The National Institute of Neurological Disorders and Stroke (NINDS) Office of Pain Policy (part of the National Institutes of Health) is soliciting public comment on the draft National Pain Strategy.

View the Draft Document

Abuse-Deterrent Opioids: Evaluation and Labeling Guidance for Industry

Source: U.S. Food and Drug Administration

This April 2015 FDA report is intended “to assist sponsors who wish to develop opioid drug products with potentially abuse-deterrent properties.” It notes that “Prescription opioid products are an important component of modern pain management. However, abuse and misuse of these products have created a serious and growing public health problem. One potentially important step towards the goal of creating safer opioid analgesics has been the development of opioids that are formulated to deter abuse. FDA considers the development of these products a high public health priority.”

Download the Report